Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology

Search Medical Condition
Please enter condition
Please choose location

Stem Cell Transplant Clinical Trials

A listing of Stem Cell Transplant medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (81) clinical trials

Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma

Busulfan Test Dose: If you agree to take part in this study, you will receive a test dose of busulfan by vein over about 60 minutes. This low-level test dose of busulfan will help the doctor decide what dose of busulfan you will receive during the study. You will most ...

Phase

Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant

This is a Phase 1/2 study evaluating the safety and feasibility of BPX-501 T cells infused after partially mismatched, related, TCR alpha beta T cell depleted hematopoietic stem cell transplant (HSCT) in pediatric patients. The purpose of this clinical trial is to determine whether BPX-501 infusion can enhance immune reconstitution ...

Phase

Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

PRIMARY OBJECTIVES: I. To assess the complete response (CR) rate with lenalidomide and sonidegib (LDE225) maintenance following an upfront single autologous stem cell transplant (SCT). SECONDARY OBJECTIVES: I. To assess the toxicity of lenalidomide and LDE225 when used as maintenance therapy in patients post autologous SCT. II. To determine the ...

Phase

Multivirus-specific T Cells for the Treatment of Virus Infections After Stem Cell Transplant

These VST lines have been made at Baylor College of Medicine from donors for other transplant patients or other normal donors some of whom were from the National Marrow Donor Program. All donors have been screened with the standard blood bank donor questionnaire, medical history and testing for infectious disease ...

Phase N/A

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

Although multiple myeloma is considered fatal, survival has dramatically improved over the last two decades with the introduction of more effective treatment options. Proteasome inhibitors have an anti-myeloma effect and are often used as either initial treatment or at relapse in patients with multiple myeloma. MLN9708 is an orally bioavailable, ...

Phase

Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases

This is a single arm dose finding study evaluating the safety and efficacy of a BPX 501 infusion (T cells genetically modified with the inducible Caspase 9 suicide gene) of 3x10E6 to 1X10E7 cells/kg followed by an AP1903 infusion on day 7 after a partially mismatched, related, T cell-depleted hematopoietic ...

Phase

MSCs With or Without Peripheral Blood Stem Cell for Treatment of Poor Graft Function and Delayed Platelet Engraftment

Allogeneic hematopoietic stem cell transplantation(allo-HSCT) is the only cure for many hematologic diseases. However, about 5-27% of patients would suffer from poor graft function (PGF) and more recipients might develop delayed platelet engraftment (DPE) after allo-HSCT. These complications are associated with considerable mortality related to infections or hemorrhagic complications. Treatment ...

Phase

Study of Elotuzumab With Lenalidomide as Maintenance After Autologous Stem Cell Transplant (ASCT)

Study Drug Administration: If you are found to be eligible to take part in this study, you will start receiving the study drugs after you have recovered from the stem cell transplant. Each study cycle is 28 days. You will receive elotuzumab by vein over about 2-4 hours on Days ...

Phase

Ixazomib After Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma in Remission

PRIMARY OBJECTIVES: I. To determine the recommended phase II dose and assess the safety of ixazomib when administered as post-transplant maintenance in mantle cell lymphoma. (Phase I) II. To assess preliminary evidence of efficacy of ixazomib when administered as post-transplant maintenance in mantle cell lymphoma. (Phase II) SECONDARY OBJECTIVES: I. ...

Phase